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Oesophageal cancerAbstract Aim: This is the first randomised study to evaluate toxicity and survival outcomes
of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesopha-
geal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. The
initial results showed comparable toxicity between regimens and pathological complete
response (pCR) rate favouring CarPacRT. Herein, we report survival, progression patterns,
and long-term toxicity after a median follow-up of 40.7 months.
Methods: NeoSCOPE was an open-label, UK multicentre, randomised, phase II trial. Eighty-
five patients with resectable OAC or GOJ adenocarcinoma, cT3 and/or cN1 (TNM v7),
suitable for neoadjuvant CRT, were recruited between October 2013 and February 2015.
Patients were randomised to OxCapRT (oxaliplatin 85 mg/m2 on Days 1, 15, and 29; cape-
citabine 625 mg/m2 orally twice daily on days of radiotherapy [RT]) or CarPacRT (carboplatin
AUC2; paclitaxel 50 mg/m2 on Days 1, 8, 15, 22, and 29). RT dose was 45 Gy/25 fractions/5
weeks. Both arms received induction chemotherapy (two cycles oxaliplatin 130 mg/m2 on Day
1, capecitabine 625 mg/m2 orally twice daily on Days 1e21) before CRT. Surgery was per-
formed 6e8 weeks after CRT.
The primary end-point was pCR. Secondary end-points were toxicity, progression-free sur-
vival (PFS), overall survival (OS), and patterns of progression.
Results: Eighty-five patients were recruited from 17 UK centres. The median OS was 41.7
months (95% confidence interval [CI] 19.6 to not reached) in the OxCapRT arm and was
not reached in the CarPacRT arm (multivariable hazard ratio [HR] Z 0.48, 95% CIs: 0.24
e0.95, P Z 0.035). The median PFS was 32.6 months (95% CIs: 17.1 to not reached) in the
OxCapRT arm and was not reached in the CarPacRT arm (multivariable HR Z 0.54, 95%
CIs: 0.29e1.01, P Z 0.053). In both arms, the distant progression was twice as common as
locoregional progression.
Conclusions: OS and PFS favoured neoadjuvant CarPacRT over OxCapRT. Distant was
more common than locoregional progression; therefore, priority should be given to optimising
the systemic treatment component.
Clinical trial information: EudraCT Number: 2012-000640-10; ClinicalTrials.gov:
NCT01843829.
ª 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Except for early stage disease, treatment by surgery
alone confers poor outcome in patients with resectable
oesophageal cancer. The CROSS trial showed that
neoadjuvant CarPacRT was associated with a doubling
of median overall survival (OS) to 49.4 months
compared with surgery alone and established a new
standard of care [1]. Oxaliplatin has been shown to be
comparable in efficacy to cisplatin in advanced gastro-
oesophageal cancer and can be conveniently delivered
as a 2-h infusion, and oxaliplatin-capecitabine was
considered as an international standard of care for
advanced gastro-oesophageal adenocarcinoma [2].
NeoSCOPE was a randomised phase II trial that
evaluated the efficacy and toxicity of OxCapRT and
CarPacRT in the neoadjuvant treatment of patients with
locally advanced resectable oesophageal adenocarci-
noma (OAC) and assessed the feasibility of safely
introducing neoadjuvant chemoradiotherapy (nCRT)
into clinical practice in the United Kingdom, where
previously neoadjuvant chemotherapy was standard of
care. The aim was to ‘pick a winner’ that could be takenforward to a future phase III trial where nCRT would be
compared with neoadjuvant chemotherapy.
The primary end-point of the trial, pathological
complete response (pCR), together with secondary end-
points of acute treatment toxicity, compliance, and
complications, was reported in 2017 when all patients
had completed surgery [3]. The analysis showed com-
parable toxicity and postoperative morbidity/mortality
in both arms (one death within 30 days of surgery in
each trial arm). Although the rate of neutropenia was
higher in CarPacRT (9/42 [21.4%] versus 1/38 [2.6%]),
this did not lead to higher incidence of neutropenic
sepsis/death. The proportion of patients undergoing
surgery and proportion of patients with microscopi-
cally negative resection margin (viable tumour >1 mm
from margin) both favoured CarPacRT (41/43 [95.3%]
and 33/41 [80.5%], respectively, versus 36/42 [85.7%]
and 26/36 [72.2%] in OxCapRT arm). The pCR rate
was also higher in the CarPacRT arm (12/41 [29.3%]
versus 4/36 [11.1%]).
Here, for the first time, we report the end-points of
OS, progression-free survival (PFS), and patterns of
progression, which were analysed when a minimum
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tients had been achieved.
2. Methods
2.1. Patients
The design of this multicentre, randomised, open-label,
‘pick a winner’, phase II trial, treatment options, eligi-
bility criteria, and follow-up modalities were previously
reported in detail [3,4]. In summary, the trial included
patients with the following key eligibility criteria:
resectable OAC including Siewert Type 1 or 2 tumour of
the gastro-oesophageal junction (GOJ; maximum
extension of 3 cm into stomach), with cT stage 3 and/
or cN stage 1 (TNM v7), World Health Organisation
performance status 0e1, maximum disease (T þ N)
length 8 cm, adequate respiratory, cardiac, haemato-
logical, renal, and hepatic function, and aged 18 years.
All patients provided written informed consent.
2.2. Randomisation
All patients fulfilling inclusion/exclusion criteria were
randomly assigned (1:1) to OxCapRT or CarPacRT by
stratified minimisation (by recruiting hospital, cT stage
[T1/T2 versus T3/T4], and cN stage [N0 versus Nþ])
with a random element (80:20) via a centralised com-
puter system.
2.3. Procedures
All patients underwent upper gastrointestinal endoscopy
with biopsy, staging computed tomography (CT), and
positron emission tomographyecomputed tomography
(PET-CT) scan and endoscopic ultrasound (unless
contraindicated). Patients in both arms received induc-
tion chemotherapy, which consisted of two 3-weekly
cycles of oxaliplatin (130 mg/m2 intravenously on Day
1) and capecitabine (625 mg/m2 orally twice daily from
Day 1 to Day 21) before starting chemoradiotherapy
(CRT). During the CRT phase, patients randomly
assigned to the OxCapRT arm received oxaliplatin
(85 mg/m2 intravenously on Days 1, 15, and 29) and
capecitabine (625 mg/m2 orally twice daily on days of
radiotherapy [RT]). The CarPacRT regime consisted of
carboplatin AUC2 and paclitaxel 50 mg/m2 adminis-
tered intravenously on Days 1, 8, 15, 22, and 29 of RT.
The RT was planned using intravenous contrast CT
simulation with minimum of 3-mm CT slices. The RT
dose was 45 Gy in 25 daily fractions, delivered Monday
to Friday as a 3D, conformally planned single-phase
treatment and prescribed according to recommenda-
tions of the International Commission on Radiation
Units and Measurements (ICRU-50). The trial included
rigorous RT quality assurance as previously
described [4,5]. Restaging CT/PET-CT was undertaken4e6 weeks after CRT, and surgery was performed at
6e8 weeks after completion of CRT. Surgical approach
was not mandated. Postoperative pathology was re-
ported with Mandard’s tumour regression grade (TRG).
Treatment toxicities were assessed as per US National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (version 4.03).
Follow-up was undertaken 3 weekly during induction
chemotherapy and weekly during the CRT phase.
Postoperative follow-up was at 30 days, 6 months, and
12 months after the surgery. Investigations and follow-
up beyond 12 months and choice of treatment at relapse
were left to the discretion of the treating clinician. Data
on events (death and progression) were collected
through case report forms.
The trial protocol was approved by the UKMedicines
andHealthcare products RegulatoryAgency and aMulti-
Centre Research Ethics Committee, sponsored by Velin-
dre University NHS Trust and coordinated by the Centre
for Trials Research at Cardiff University. The trial was
funded by Cancer Research UK (C44694/A14614), who
had no role in study design, data collection, data analysis,
data interpretation, or publication of the results. The lead
authors (S.M., C.H., and T.C.) had full access to the data
and final responsibility to submit for publication.
2.4. End-points
The primary end-point of the trial was pCR rate. Sec-
ondary end-points were feasibility of recruitment,
toxicity, perioperative morbidity/mortality, circumferen-
tial resection margin positivity rate, and survival. The
primary end-point and early toxicity data have been
previously reported [3]. Herein we report, for the first
time, OS (time-to-event), PFS (time-to-event), and pat-
terns of progression and late toxicity at 6 and 12 months.
2.5. Statistical analysis
Data were analysed according to a prespecified statisti-
cal analysis plan using the Stata SE 16 statistical pack-
age (StataCorp, College Station, Texas 77845 USA).
PFS was defined as the interval between randomisation
and the earliest occurrence of disease progression
resulting in primary (or perioperative) irresectability of
disease, locoregional recurrence (after completion of
therapy), distant dissemination (during or after
completion of treatment), or death from any cause. As
in the CROSS trial, this definition for PFS was taken
from the modified STEEP criteria for neoadjuvant
treatment trials [6]. OS was defined as the interval be-
tween randomisation and death from any cause. Pa-
tients who were event free were censored at the time they
were last known to be event free. We estimated event
time distributions with the KaplaneMeier method and
compared OS and PFS with hazard ratios (HRs) from
Cox regression in univariable and multivariable models.
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thought a priori to have a prognostic effect (including
the randomisation stratification variables and others; see
Table 1) and included treating centre as a random frailty
effect. We tested the proportional hazards assumption
of each model with Cox-Snell residuals and Schoenfeld’s
global test. Three- and 5-year survival were estimated
using life tables with actuarial adjustment. Survival an-
alyses were primarily in the intention-to-treat (ITT)
population with sensitivity analyses in the per-protocol
(PP) population who received at least one cycle of
chemotherapy on the allocated CRT regimen. Numbers
needed to treat to prevent death were calculated using
methods published elsewhere [7]. Toxicity analyses were
conducted in the PP population who received surgery
and toxicity assessments at the follow-up time points.
3. Results
3.1. Study population
Between 10th October 2013 and 12th February 2015, 85
patients were registered into the trial from 17 hospitals
across the United Kingdom and 77 underwent surgery
(Fig. 1). Patient and tumour baseline characteristics were
balanced between the groups (eTable 1 in Supplement 2).
The minimum follow-up for surviving patients was 3 years
with a median follow-up time of 43.4 (95% confidence in-
terval [CI]: 37.7e53.6) and 51.0 (95% CI: 45.5e54.3)
months in the OxCapRT and CarPacRT arm, respectively.
At the time of analysis, 37 patients had died (21/42 [50%] in
OxCapRT arm and 16/43 [37%] in CarPacRT arm).
3.2. Overall survival
The analysis of OS in the ITT population (n Z 85) is
shown in Table 1. At the time of analysis, 48 of 85Table 1
Univariable and multivariable Cox regression overall survival analyses.
Baseline variable Univariable Cox
HR P value
Trial arm OxCapRT 1.00
CarPacRT 0.56 0.079
T stage 1 or 2 1.00
3 or 4 0.63 0.388
N stage N0 1.00
Nþ 1.80 0.124
Age (years) <65 1.00
65þ 2.12 0.028
WHO PS 0 1.00
1 1.60 0.241
Tumour length <6 cm 1.00
6 cm 0.98 0.961
Sex Male 1.00
Female 2.06 0.045
CI, confidence interval; HR, hazard ratios; WHO PS, World Health Orga
a Including all variables in this table and treating centre as a shared fraipatients were alive; 21 of 42 (50%) in the OxCapRT arm,
and 27 of 43 (63%) in the CarPacRT arm (Table 2). The
median OS was 41.72 months (95% CI 19.58 to not
reached) in the OxCapRT arm (Fig. 2a) and was not
reached in the CarPacRT arm. Three- and 5-year OS
were 52% (95% CI: 35%e67%) and 39% (95% CI: 21%e
56%) in the OxCapRT arm and 74% (95% CI: 58%e
85%) and 54% (95% CI: 33%e70%) in the CarPacRT
arm, respectively. The evidence for this treatment effect
favouring CarPacRT was statistically significant in the
multivariable analysis (HR Z 0.48, 95% CIs: 0.24e0.95,
P Z 0.035). The treatment effect was consistent in
magnitude across subgroups (eFig. 1 in Supplement 2).
In the PP population (those who started their allocated
chemoradiotherapy regimen, n Z 77), the treatment
effect was of a similar magnitude, although it did not
reach statistical significance at the 5% level (multivari-
able HRZ 0.54, 95% CIs: 0.25e1.14, PZ 0.106). It can
also be seen from Table 1 that there was some evidence
that lower age and being male were both associated with
better survival. Causes of death and 30- and 90-day
postsurgery mortality are given in e.Table 2 in
Supplement 2 The estimated number of patients who
need to be treated with CarPacRT to prevent one
additional death at 5 years was 4.1 (95% CI 2.6e53.2).
3.3. Progression-free survival
At the time of analysis, 42 of 85 patients were alive and
free of disease (18/42 [43%] in the OxCapRT arm and
24/43 [56%] in the CarPacRT arm). In the ITT popu-
lation, the median PFS was 32.6 months (95% CIs: 17.1
to not reached) in the OxCapRT arm and was not
reached in the CarPacRT arm (Fig. 3a). Proportion of
patients progression free at 1 year (68% [95% CI: 52e80]
versus 81% [95% CI: 66e90]), 3 years (47% [95% CI:
30e61] versus 63% [95% CI: 47e75]) and 5 years (19%Multivariable Coxa
95% CIs HR P value 95% CIs
1.00
0.29e1.07 0.48 0.035 0.24e0.95
1.00
0.22e1.80 0.62 0.415 0.20e1.95
1.00
0.85e3.83 1.25 0.586 0.56e2.80
1.00
1.09e4.13 2.02 0.052 0.99e4.09
1.00
0.73e3.50 1.37 0.457 0.60e3.14
1.00
0.51e1.88 1.03 0.935 0.53e2.01
1.00
1.02e4.18 2.25 0.037 1.05e4.81
nisation performance status.
lty.
Fig. 1. CONSORT flow diagram of trial participants.
S. Mukherjee et al. / European Journal of Cancer 153 (2021) 153e161 157[95% CI: 2e51]) versus 51% [95% CI: 32e67]) favoured
CarPacRT. The evidence for this treatment effect
favouring CarPacRT was stronger in the multivariable
analysis (HR Z 0.54, 95% CIs: 0.29e1.01, P Z 0.053)
than the univariable (HRZ 0.59, 95% CIs: 0.32e1.07, P
Z 0.084). In the PP population (those who started their
allocated chemoradiotherapy regimen, n Z 77), the
treatment effect was of a similar magnitude (multivari-
able HR Z 0.58, 95% CIs: 0.29e1.19, P Z 0.137) but
did not reach statistical significance.3.4. Patterns of progression
Table 2 summarises patterns of progression, and Fig. 3b
and c represents KaplaneMeier curves for locoregional
PFS and distant PFS. Of the 27 patients with disease
progression, seven had locoregional site of first progres-
sion, 17 relapsed systemically, and three had combinedlocoregional and systemic progression. In both the ITT
population and those patients receiving allocated treat-
ment and surgery, there were approximately twice
as many distant than locoregional progressions in both
trial arms.
Of the 72 patients who received allocated the CRT
regimen and had surgery, 70 were assessable for Man-
dard’s TRG (one as missing and one was ypT0, ypN1).
Of these, 43 patients had Mandard’s TRG 1 or 2 on
resection, and of those, seven patients had a distant
recurrence detected first, zero had a local recurrence
detected first, eight died before recurrence, and 28 were
still alive without recurrence. Twenty-seven patients had
Mandard’s TRG 3 or 4 on resection (no patients were
TRG 5), and of those, four patients had a distant
recurrence detected first, seven had a local (or local and
distant) recurrence detected first, four died before
recurrence, and 12 were still alive without recurrence.
Table 2
Patterns of disease progression.
OxCapRT CarPacRT
All patients N Z 42 N Z 43
n % n %
Alive and without progression 18 43 24 56
Died before progression detected 8a 19 8b 19
Progression detected prior to death 16 38 11 26
Locoregional first 4 10 3 7
Metastatic first 10 24 7 16
Both 2 5 1 2
All patient who received allocated CRT regimen and had surgery N Z 31 N Z 41
n % n %
Alive and without progression 17 55 24 59
Died before progression detected 5a 16 7b 17
Progression detected prior to death 9 29 10 24
Locoregional first 2 6 3 7
Metastatic first 5 16 6 15
Both 2 6 1 2
a Two oesophageal cancer.
b One oesophageal cancer.
S. Mukherjee et al. / European Journal of Cancer 153 (2021) 153e161158The median OS was 49.6 (95% CIs: 30.1 to not reached)
in the TRG 3/4 patients and was not reached in the
TRG 1/2 patients (HR Z 1.49, 95% CIs: 0.70e3.17, P
Z 0.301; Fig. 2b).3.5. Late toxicity
We have previously reported the rates of acute toxicity
rate for our patients [3]. eTable 3 in Supplement 2 shows
the Grade 3 or 4 toxicities experienced by patients at
6 and 12 months postsurgery. There were more patients
who experienced at least one Grade 3 or 4 toxicity at 6
months in the OxCapRT arm: 4/27 (15%) versus 1/38
(3%; l2 Z 3.300, PZ 0.069), but at 12 months, only one
patient in each arm had a Grade 3 or 4 toxicity. eTable 4
in Supplement 2 shows that there were fewer persistent
Grade 1/2 toxicities observed at both 6 and 12 months
postsurgery in the OxCapRT arm: 8/25 (32%) versus 15/Fig. 2. KaplaneMeier curves34 (44%; l2 Z 0.889, P Z 0.346). Neither comparison
was statistically significant.4. Discussion
The mature follow-up of the NeoSCOPE trial demon-
strates superior OS in the CarPacRT arm. This only
reaches statistical significance in the ITT multivariable
analysis, but the magnitude of the treatment effect is
similar in the PP analysis and consistent across sub-
groups and PFS analyses. In addition, there was some
evidence that lower age and being male were both
associated with better OS. In both groups, systemic
progression was more common than locoregional pro-
gression. Patients who achieved Mandard TRG 1-2 after
CRT had no local recurrences and better survival, but
this did not reach statistical significance. A greater
proportion of patients on OxCapRT had residual Grade
3/4 toxicities at 6 months postsurgery, but this was notfor the overall survival.
Fig. 3. KaplaneMeier curves for progression-free survival by trial arm.
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difference between the arms). Broadly, the results are
consistent with our initial report, which also favoured
the CarPacRT arm by demonstrating a higher pCR and
R0 rate with acceptable toxicity.
The CROSS trial established CarPacRT as a stan-
dard of care for resectable oesophageal cancer; however,
the trial included a mix of squamous cell carcinoma
(SCC) and adenocarcinoma (AC), with the magnitude
of benefit being much larger in patients with SCC
(HR 0.48) [8]. On the other hand, the HR for benefit for
AC seen in the CROSS trial (HR 0.73) was similar to
trials of pre- and peri-operative chemotherapy (OE02
[9], MAGIC [10], and ACCORD 07 [11]), and it is not
clear whether nCRT or neoadjuvant chemotherapy
(nCT) is the preferred option. One randomised phase II
study of nCT versus nCRT, which predominantly
included AC patients (73%), failed to show OS benefit in
the CRT group, although R0 resection rates were better
and lymph node positivity lower with nCRT [12]. For
NeoSCOPE, we therefore only included patients with
AC, by far the more common histology in Western
countries. We evaluated OxCapRT, as fluoropyr-
imidine/platinum combination has proven activity in
OAC. At the time of designing the trial, oxaliplatin-
capecitabine was considered as an internationalstandard of care for advanced gastro-oesophageal
adenocarcinoma. We also included induction chemo-
therapy before CRT, as we postulated that additional
cycles of chemotherapy would allow better management
of micrometastatic disease.
The pCR and survival outcomes in the CarPacRT
arm of NeoSCOPE are similar to those in the AC cohort
in the CROSS trial [1,8]. Since the completion of Neo-
SCOPE, the standard of care for perioperative chemo-
therapy in gastric/GOJ adenocarcinoma has shifted to
the triple combination of 5FU, oxaliplatin, and doce-
taxel (FLOT), which demonstrated OS superiority over
epirubicin, cisplatin, and capecitabine (ECX) [13]. Pa-
tients in the CarPacRT arm of NeoSCOPE were
exposed to the triple combination of fluoropyrimidine,
platinum, and taxane (although sequentially rather than
concurrently), and this may be one of the reasons that
accounted for superior survival seen in that treatment
arm. A randomised control trial of FLOT versus Car-
PacRT in the neoadjuvant treatment of oesophageal
cancer is currently underway (ESOPEC trial) [14].
The pattern of progression (overall 32% [27/85],
locoregional progression 11.8% [10/85], and systemic
progression 23.5% [20/85]) is similar to patterns of
progression seen in CROSS trial [15]. Despite the use of
induction chemotherapy, there was a predominance of
S. Mukherjee et al. / European Journal of Cancer 153 (2021) 153e161160systemic relapse in this phase 2 study. Although the
study was not designed to demonstrate the added benefit
of induction systemic therapy, the predominance of
systemic failures raises the potential need for ‘better’
rather than ‘more’ chemotherapy. Sequential integration
of induction FLOT followed by CarPacRT can poten-
tially lead to more effective control of both systemic and
local components of oesophageal cancer and could be
tested in future trials; however, unselective use of sys-
temic agents is unlikely to lead to step-change
improvement in outcomes. However, careful consider-
ation of the potential incremental risk to patient treat-
menterelated morbidity with increasing systemic agents
needs to be taken into account. In our study, we have
previously reported our acute toxicity rates [3]. It is
noteworthy that the rate of febrile neutropenia in our
cohort was 0 in the induction chemotherapy arm and
2.4% in the CarPacRT, which is significantly lower than
noted in patients who received FLOT (51%) chemo-
therapy [14]. It may be that sequential FLOT followed
by CarPacRT reduces the rate of cumulative myelo-
suppressive toxicity by potentially reducing the number
of cycles of FLOT chemotherapy required to maintain
patient responses and clinical outcomes. The risk of
myelosuppression with this sequential approach may be
further mitigated with the use of prophylactic haemo-
poietic growth factors and newer radiation technologies
such as proton beam therapy [16].
With our evolving knowledge of the genetic land-
scape of OAC, we may be able to identify actionable
targets, allowing personalisation of treatment strategies
based on individual tumour profiles [17].
4.1. Limitations and strengths
This is the first randomised study to have compared two
preoperative chemoradiation regimens in a purely
adenocarcinoma cohort. This trial was not powered to
compare survival between arms, and OS was a secondary
end-point. Of the 42 patients randomised to the
OxCapRT arm, only 36 underwent surgery (compared
with 41 of 43 randomised patients in the CarPacRT arm)
as more patients had disease progression (3 versus 1) and
toxic death (2 versus 1) in the OxCapRT arm. Moreover,
three patients crossed over to CarPacRT arm because of
toxicity during induction chemotherapy. However, the OS
results were consistent in ITT and PP analyses. In addi-
tion, we did not collect data regarding what proportion of
locoregional progression occurred within the surgical and
RT fields, although we did note that the majority of the
progressions were distant rather than locoregional.
5. Conclusions
NeoSCOPE demonstrated that in patients with resect-
able OAC or GOJ adenocarcinoma, OS and PFS fav-
oured neoadjuvant CarPacRT over OxCapRT. Acrossboth arms, distant was more common than locoregional
progression, suggesting priority should be given to
optimising the systemic component of treatment.
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